A partnership has been struck between Astellas and Phenomic AI through Astella’s wholly-owned subsidiary Xyphos Biosciences. The focus of this collaboration will be on the examination of the potential of antibodies, which have been developed by Phenomic and are designed for a new tumor stroma target identified via Phenomic’s scTx platform. These antibodies could enhance cell therapy strategies for the treatment of solid tumors.
According to the terms of the agreement, Phenomic will receive an upfront payment, full research funding, and a milestone payment. Astellas, on the other hand, will maintain the first right to negotiate a license for these antibodies throughout the agreement.
Phenomic CEO Discusses Solid Tumor Cell Therapy in Collaboration with Astellas
Phenomic CEO Girish Aakalu expressed enthusiasm about the potential of their antibodies to improve cell therapies for solid tumors by targeting the tumor stroma. He also welcomed the opportunity to collaborate with the Astellas team and lauded their deep cell therapy expertise.
The scTx single-cell transcriptomics platform of Phenomic AI is utilized to pioneer a unique approach to solid cancer drug discovery and development. This platform’s vast database and machine learning engine provide insights into tumor stroma, a significant obstacle to cancer therapies, at a resolution not previously achievable.
Astellas Pharma’s Acquisitions Pave the Way for Innovative Tumor Treatment with Phenomic AI
Earlier this year, Astellas Pharma completed the acquisition of Iveric Bio, through its indirect wholly-owned subsidiary, Berry Merger Sub. In another deal this year, Astellas Pharma’s subsidiary agreed to purchase 100% of the outstanding shares of Iveric Bio for $40 per share in cash, amounting to a total equity value of around $5.9bn.
The partnership between Phenomic AI and Astellas is a significant step forward in the development of innovative approaches to solid cancer treatment, potentially enhancing cell therapy strategies for the treatment of solid tumors.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
